FDG-PET to assess infections: a review of the evidence

Tsakonas E, Moulton K, Spry C
Record ID 32008100104
English
Authors' objectives:

There is no Canadian guidance on the use of FDG-PET in infections at the present time. The purpose of this report was to research and critically appraise the recent evidence on the effectiveness, safety, cost-effectiveness, and linical impact of FDG-PET compared with ther imaging methods in the diagnosis and anagement of infection, with the objective of
informing guidance and policy on the use of FDG-PET for this indication.
1. What is the evidence for the safety and clinical effectiveness of FDG-PET compared to other imaging techniques for the detection, characterization, or management of infections?
2. What is the cost-effectiveness of FDG-PET compared to other imaging techniques for the detection, characterization, or management of infections?
3. What is the evidence that FDG-PET alters or improves treatment of patients with infection?

Authors' recommendations: Although suggestive of relative effectiveness in some indications, there is a lack of high-level evidence regarding the effectiveness of FDGPET across indications and within a range of comparators. More intensive studies or systematic reviews and analyses of specific indications are needed, as well as evidence for this technology’s potential to alter patienttreatment and outcomes. Assessments of costeffectiveness and of the possible impact on resource allocation and wait times are also required.
Authors' methods: Review
Details
Project Status: Completed
Year Published: 2008
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Canada
  • Infections
  • Positron-Emission Tomography
  • Radiotherapy Planning, Computer-Assisted
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.